MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584298 | Name: Buflomedil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Buflomedil is a vasoactive agent that has been used for peripheral arterial diseases.

Chemical Structure

Buflomedil
Buflomedil
CAS#55837-25-7 (free base)

Theoretical Analysis

MedKoo Cat#: 584298

Name: Buflomedil

CAS#: 55837-25-7 (free base)

Chemical Formula: C17H25NO4

Exact Mass: 307.1784

Molecular Weight: 307.39

Elemental Analysis: C, 66.43; H, 8.20; N, 4.56; O, 20.82

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
55837-25-7 (free base) 35543-24-9 (HCl)
Synonym
Buflomedil; Buflomedilum
IUPAC/Chemical Name
1-Butanone, 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-
InChi Key
OWYLAEYXIQKAOL-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3
SMILES Code
O=C(C1=C(OC)C=C(OC)C=C1OC)CCCN2CCCC2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 307.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: de Backer TL, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD000988. doi: 10.1002/14651858.CD000988.pub4. Review. PubMed PMID: 23543509. 2: Bucolo C, Longo L, Camillieri G, Drago F, Salomone S. Safety profile assessment of buflomedil: an overview of adverse reactions between 1975 and 2011. Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1190-6. doi: 10.1002/pds.3328. Epub 2012 Jul 31. Review. PubMed PMID: 22855302. 3: Tsantilas D, Hatzitolios AI, Tziomalos K, Karamitsos D, Papadimitriou D. Effects of buflomedil on skin blood flow in patients with type 2 diabetes mellitus without overt micro- or macroangiopathy. Int Angiol. 2011 Apr;30(2):164-71. PubMed PMID: 21427654. 4: Wu S, Zeng Q, Liu M, Yang J, He S, Lin S, Wu B. Buflomedil for acute ischaemic stroke. Cochrane Database Syst Rev. 2015 Jul 20;(7):CD009570. doi: 10.1002/14651858.CD009570.pub2. Review. PubMed PMID: 26193704. 5: El-Desoky HS, Ghoneim MM, Abdel-Galeil MM. Quantification of the Vasoactive Agent Buflomedil HCl in Pharmaceutical Formulation and Human Serum by Stripping Voltammetry and Liquid Chromatography. Acta Chim Slov. 2010 Jun;57(2):332-40. PubMed PMID: 24061728. 6: Papa P, Rocchi L, Mainardi C, Donzelli G. Buflomedil interference with the monoclonal EMIT d.a.u. amphetamine/methamphetamine immunoassay. Eur J Clin Chem Clin Biochem. 1997 May;35(5):369-70. PubMed PMID: 9189741. 7: Le Dévéhat C, Vimeux M, Bondoux G, Khodabandehlou T. Effects of buflomedil on microvascular disorders in diabetic patients. Blood Vessels. 1991;28 Suppl 1:38-43. PubMed PMID: 1932765. 8: Tang JR, Wu L, Su JH, Zhang P, Yu LB, Xiao H. Vasoactive agent buflomedil up-regulated expression of vascular endothelial growth factor in a rat model of sciatic nerve crush injury. Indian J Pharmacol. 2012 Jul-Aug;44(4):480-4. doi: 10.4103/0253-7613.99312. PubMed PMID: 23087509; PubMed Central PMCID: PMC3469951. 9: Kushiku K, Ohba M, Mikagi T, Nuki S, Araki Y, Furukawa T. Cardiovascular actions of buflomedil and possible mechanisms involved. Arzneimittelforschung. 1989 Jun;39(6):670-7. PubMed PMID: 2775333. 10: de Backer TL, Bogaert M, Vander Stichele R. Buflomedil for intermittent claudication. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000988. doi: 10.1002/14651858.CD000988.pub3. Review. Update in: Cochrane Database Syst Rev. 2013;3:CD000988. PubMed PMID: 18253982. 11: Jeremy JY, Gill J, DuBourg A, Pelat P, Mikhailidis DP. Effect of buflomedil on in vitro prostacyclin and endothelin synthesis by vascular (rat and human) and penile (rat) tissue and calcium uptake by isolated human platelets. Int J Impot Res. 1993 Sep;5(3):139-47. PubMed PMID: 8124432. 12: Clissold SP, Lynch S, Sorkin EM. Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases. Drugs. 1987 May;33(5):430-60. Review. PubMed PMID: 3297620. 13: Buflomedil: still too many fatal cardiac and neurological events. Prescrire Int. 2011 Apr;20(115):99. PubMed PMID: 21648214. 14: Trübestein G, Balzer K, Bisler H, Klüken N, Muller-Wiefel H, Unkel B, Mahfoud Y, Ziegler W. Buflomedil in arterial occlusive disease: results of a controlled multicenter study. Angiology. 1984 Aug;35(8):500-5. PubMed PMID: 6383127. 15: Mauad RJ Jr, Shimizu MH, Mauad T, de Tolosa EM. Buflomedil and pentoxifylline in the viability of dorsal cutaneous flaps of rats treated with nicotine. J Plast Reconstr Aesthet Surg. 2006;59(4):387-92. PubMed PMID: 16756255. 16: Molinaro M, Regazzi MB, Raffaghello S, Buggia I, Iacona I, Graziani P, Specchia G, Melzi D'eril G. Evaluation of two buflomedil tablet formulations in patients with atherosclerotic disease. J Clin Pharm Ther. 1994 Apr;19(2):111-5. PubMed PMID: 8071390. 17: Gundert-Remy U, Weber E, Lam G, Chiou WL, Mann W, Aynilian GH. The clinical pharmacokinetics of buflomedil in normal subjects after intravenous and oral administration. Eur J Clin Pharmacol. 1981;20(6):459-63. PubMed PMID: 7286057. 18: Diamantopoulos EJ, Grigoriadou M, Ifanti G, Raptis SA. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication. Int Angiol. 2001 Dec;20(4):337-44. PubMed PMID: 11782701. 19: Wang W, Yang YN, Ma XM, Bu P, Sun L. [Microbial transformation of buflomedil by Cunninghamella blakesleana AS 3.153]. Yao Xue Xue Bao. 2012 Jul;47(7):934-40. Chinese. PubMed PMID: 22993861. 20: Bachand RT, Dubourg AY. A review of long-term safety data with buflomedil. J Int Med Res. 1990 May-Jun;18(3):245-52. PubMed PMID: 2193838.